Detection of High-grade Bladder Cancer in Urine Samples Using In Situ Hybridization of Long Noncoding RNA UCA1
- PMID: 40374004
- DOI: 10.1016/j.urology.2025.05.012
Detection of High-grade Bladder Cancer in Urine Samples Using In Situ Hybridization of Long Noncoding RNA UCA1
Abstract
Objective: To evaluate the performance of urinary biomarker long noncoding RNA urothelial carcinoma-associated 1 (UCA1) in detection of high-grade bladder cancer (BCa) using RNA in situ hybridization (RISH). Urine cytology and cystoscopy are the gold standard for BCa detection. There is a paucity of reliable urinary biomarkers for BCa detection in clinical practice.
Methods: TCGA and Cancer Cell Line Encyclopedia databases were utilized to analyze the expression pattern of UCA1 in BCa surgical specimens and cell lines. A method for detection of UCA1 expression on cytology slides was developed. Urine and pathology samples were collected from patients undergoing trans-urethral resection of bladder tumor or radical cystectomy. Performance of RISH and cytology were evaluated for detection of high-grade BCa, vs low-grade and no BCa. The sensitivity, specificity, positive predictive value, negative predictive value (NPV) of RISH alone, cytology alone, and sequential use of cytology followed by RISH in cases of atypical or negative cytology were calculated.
Results: UCA1 was significantly upregulated in BCa tissues compared to normal controls. In 50 patients with a confirmed diagnosis of BCa, urine cytology had a sensitivity 34.4%, NPV 36.4% for detection of high grade BCa. RISH had a sensitivity 66.7%, NPV 50%. Sequential testing including both cytology and RISH revealed a sensitivity 78.1%, NPV 53.3%.
Conclusion: UCA1 improves sensitivity and NPV of urine cytology alone for detection of high grade BCa. This pilot study demonstrates potential utility of UCA1 as a urinary biomarker to augment cytology for screening and surveillance of high grade BCa.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors have no conflict of interest to declare.
Similar articles
-
Diagnostic and prognostic value of bladder cancer-related transcript markers in urine.J Cancer Res Clin Oncol. 2016 Feb;142(2):401-14. doi: 10.1007/s00432-015-2037-8. Epub 2015 Sep 2. J Cancer Res Clin Oncol. 2016. PMID: 26328914 Free PMC article.
-
Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.Health Technol Assess. 2010 Jan;14(4):1-331, iii-iv. doi: 10.3310/hta14040. Health Technol Assess. 2010. PMID: 20082749
-
Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection.J Cancer Res Clin Oncol. 2017 Sep;143(9):1757-1769. doi: 10.1007/s00432-017-2433-3. Epub 2017 May 8. J Cancer Res Clin Oncol. 2017. PMID: 28484844 Free PMC article. Clinical Trial.
-
Sensitivity of urine cytology in detecting high-grade urothelial carcinoma in patients with neoplastic urinary bladder diverticula: A major cancer center experience.Cancer Cytopathol. 2024 Mar;132(3):144-151. doi: 10.1002/cncy.22782. Epub 2023 Dec 6. Cancer Cytopathol. 2024. PMID: 38054371 Free PMC article.
-
Novel urinary biomarkers for the detection of bladder cancer: A systematic review.Cancer Treat Rev. 2018 Sep;69:39-52. doi: 10.1016/j.ctrv.2018.05.012. Epub 2018 May 29. Cancer Treat Rev. 2018. PMID: 29902678
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical